Metabolic Effects of Gastrointestinal Surgery in T2DM
Status:
Unknown status
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Gastric bypass surgery resolves type 2 diabetes mellitus (T2DM) without the need for diabetes
therapy in ~80% of patients. Moreover, improvement in insulin sensitivity and glucose
homeostasis occurs within days after surgery before significant weight loss is achieved. This
observation has led to the notion that bypassing the upper gastrointestinal (GI) tract has
specific therapeutic effects on insulin action and glucose metabolism. In fact, both surgical
and endoscopic procedures that bypass the upper GI tract are currently being studied in human
subjects. Recently, a new surgical technique, duodenal-jejunal bypass surgery (DJBS), has
been developed specifically to treat T2DM. Data from preliminary studies have shown that DJBS
results in glycemic control in 87% of overweight and obese patients with T2DM.These subjects
will undergo metabolic studies at the University Hospital in Sao Paulo before and after their
surgical procedure. Washington University investigators will: 1) provide technical support
and guidance to the physicians performing the studies in Brazil, 2) process and analyze blood
samples obtained from the study at the Washington University Center for Human Nutrition, and
3) be involved in analyzing the data and writing the final manuscripts. The effects of DJBS
on the following clinical and metabolic parameters will be evaluated